AbbVie Inc.
ABBV · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $16 | $15 | $13 | $15 |
| % Growth | 2.3% | 15.6% | -11.6% | – |
| Cost of Goods Sold | $3 | $2 | $4 | $4 |
| Gross Profit | $12 | $13 | $9 | $11 |
| % Margin | 78.5% | 84.4% | 70% | 70.9% |
| R&D Expenses | $2 | $2 | $2 | $7 |
| G&A Expenses | $0 | $0 | $0 | $1 |
| SG&A Expenses | $3 | $3 | $3 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $2 |
| Other Operating Expenses | $2 | $2 | $0 | $3 |
| Operating Expenses | $7 | $7 | $6 | $12 |
| Operating Income | $5 | $6 | $4 | -$1 |
| % Margin | 31% | 38% | 28% | -9.9% |
| Other Income/Exp. Net | -$4 | -$4 | -$2 | -$1 |
| Pre-Tax Income | $1 | $2 | $2 | -$2 |
| Tax Expense | $1 | $1 | $0 | -$2 |
| Net Income | $0 | $1 | $1 | -$0 |
| % Margin | 1.2% | 6.1% | 9.6% | -0.1% |
| EPS | 0.1 | 0.53 | 0.72 | -0.018 |
| % Growth | -81.1% | -26.4% | 4,077.9% | – |
| EPS Diluted | 0.1 | 0.53 | 0.72 | -0.018 |
| Weighted Avg Shares Out | 2 | 2 | 2 | 2 |
| Weighted Avg Shares Out Dil | 2 | 2 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $1 | $1 |
| Depreciation & Amortization | $2 | $2 | $2 | $2 |
| EBITDA | $3 | $4 | $4 | $1 |
| % Margin | 21.8% | 28.2% | 33% | 3.5% |